The short answer
MOTS-c activates AMP-activated protein kinase without raising the AMP-to-ATP ratio. It inhibits the folate cycle and de novo purine biosynthesis, causing the endogenous AMPK activator AICAR to accumulate. AMPK activation follows from that accumulation, making the mechanism metabolite-mediated rather than direct.
Key facts
- Target pathway
- Folate cycle / de novo purine biosynthesis
- Accumulating metabolite
- AICAR
- Downstream kinase
- AMPK
- Canonical AMPK trigger
- Rising AMP:ATP ratio (not used here)
- Reported downstream effect
- GLUT4 translocation
- Primary reference
- Lee et al., Cell Metab 2015 (PMID 25738459)
What AMPK is and why it matters
AMP-activated protein kinase is the cell's principal energy sensor. When energy charge falls, AMPK switches the cell from anabolic to catabolic behaviour, increasing glucose uptake and fatty-acid oxidation, suppressing synthetic pathways. It is normally activated by AMP and ADP binding directly to its gamma subunit, which is why AMPK activation is usually understood as a direct readout of the AMP-to-ATP ratio.
The route MOTS-c takes instead
MOTS-c does not raise the AMP-to-ATP ratio. It interferes with the folate cycle, the one-carbon metabolic pathway that supplies carbon units for de novo purine biosynthesis. Blocking that pathway causes AICAR (an intermediate of purine synthesis and a well-characterised endogenous AMPK activator) to build up. AMPK then responds to AICAR. The peptide never touches AMPK itself.
Research material referenced
MOTS-C 10mg, third-party HPLC tested
Why AICAR is the relevant intermediate
AICAR is structurally an AMP mimetic. Once phosphorylated inside the cell to ZMP, it binds the same regulatory site on AMPK that AMP occupies. This is not a novel mechanism invented for MOTS-c. AICAR has been used as a laboratory AMPK activator for decades. What MOTS-c does is raise it endogenously by constricting the pathway that consumes it.
How this differs from metformin
Metformin is also an indirect AMPK activator, but by a different route: it inhibits mitochondrial complex I, which lowers ATP production and does raise the AMP-to-ATP ratio. MOTS-c arrives at the same kinase through one-carbon metabolism without impairing respiration. Two indirect activators, two entirely different upstream mechanisms.
Reported downstream effects
The 2015 paper reported GLUT4 translocation and effects on glucose handling in mouse models, consistent with AMPK activation. Later work has examined mitochondrial respiration in tissue models. All of this is preclinical, and the effects are reported for the models studied rather than established for humans.
Why the indirectness is scientifically interesting
A mitochondrially encoded peptide that regulates a cytosolic energy sensor through a one-carbon metabolic pathway is a unusual signalling architecture. It connects mitochondrial gene expression to nuclear-genome-encoded metabolism through a diffusible small-molecule intermediate, which is a different kind of communication from a receptor-ligand interaction.
Frequently asked questions
Does MOTS-c bind AMPK directly?
No. It acts upstream, on the folate cycle, and AMPK responds to the resulting AICAR accumulation.
Is this the same mechanism as metformin?
No. Both activate AMPK indirectly, but metformin inhibits complex I and raises the AMP-to-ATP ratio, while MOTS-c works through one-carbon metabolism.
What is AICAR?
5-aminoimidazole-4-carboxamide ribonucleotide, an intermediate of purine synthesis that acts as an AMP mimetic and activates AMPK once phosphorylated to ZMP.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedLee C et al., Cell Metabolism 2015 (PMID 25738459)pubmed.ncbi.nlm.nih.gov
- RefMOTS-c: a promising mitochondrial-derived peptide. PMCpmc.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More MOTS-c (Mitochondrial Peptide) articles
- MOTS-c Nuclear Translocation Under Metabolic StressIn 2018 MOTS-c was shown to move into the nucleus under metabolic stress and regulate antioxidant response element genes - retrograde signalling from mtDNA.
- MOTS-c and Exercise: What the Published Research ShowsReynolds et al. reported MOTS-c rises about 12-fold in human skeletal muscle after exercise and 1.6-fold in circulation. What the 2021 paper actually found.
- MOTS-c CAS Number and Chemical IdentityMOTS-c carries CAS 1627580-64-6, PubChem CID 146675088 and UNII A5CV6JFB78 - the identifiers that let a certificate be checked against the literature.
- MOTS-c Storage, Stability and ReconstitutionMOTS-c carries two oxidation-prone methionines. Why lyophilised material is stored cold and dark, and what governs stability once it is in solution.
- MOTS-c vs Humanin: How They DifferHumanin and MOTS-c are both mitochondrial-derived peptides but differ in gene of origin, length, receptor biology and research focus. A side-by-side comparison.